Pierrel SpA (“Pierrel”), a global provider of pharmaceutical and life science industries listed and traded on the Italian Stock Exchange (Milan Stock Exchange: PRL) and mondoBIOTECH holding AG (“MondoBiotech”) a Swiss-based unconventional drug discovery company focused on rare and neglected diseases listed and traded on the SIX Swiss Exchange (SIX: RARE) announce today that they have entered into exclusive negotiations, with regard to a potential business combination of the Contract Research Organization (CRO) of Pierrel with mondoBIOTECH.